The DOI matches its Crossref record; 558 of the 558 references it cites were found in a registry or an index.
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
NON-INVASIVE MAGNETIC STIMULATION OF HUMAN MOTOR CORTEX
Barker, A. T., Jalinous, R., & Freeston, I. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92413-4 · Cited by 4,460
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J.-P. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,081
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop
Parent, A., & Hazrati, L.-N. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00007-c · Cited by 2,161
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Van Tol, H. H. M., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,014
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Pathological synchronization in Parkinson's disease: networks, models and treatments
Hammond, C., Bergman, H., & Brown, P. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.05.004 · Cited by 1,629
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Neurotransmitters and neuromodulators in the basal ganglia
Graybiel, A. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90104-i · Cited by 1,576
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors
Caulfield, M. P., & Birdsall, N. J. M. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01362-0 · Cited by 1,474
Functional significance of the cortico-subthalamo-pallidal “hyperdirect” pathway
Nambu, A., Tokuno, H., & Takada, M. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00027-5 · Cited by 1,371
Parent, A., & Hazrati, L.-N. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00008-d · Cited by 1,358
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor
Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., Nakanishi, S., Jingami, H., & Morikawa, K. (2000) · Nature · doi:10.1038/35039564 · Cited by 1,249
Histamine in the Nervous System
Haas, H. L., Sergeeva, O. A., & Selbach, O. (2008) · Physiological Reviews · doi:10.1152/physrev.00043.2007 · Cited by 1,228
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217
Dynorphin Is a Specific Endogenous Ligand of the κ Opioid Receptor
Chavkin, C., James, I. F., & Goldstein, A. (1982) · Science · doi:10.1126/science.6120570 · Cited by 1,168
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1
Sunahara, R. K., Guan, H.-C., O'Dowd, B. F., Seeman, P., Laurier, L. G., Ng, G., George, S. R., Torchia, J., Van Tol, H. H. M., & Niznik, H. B. (1991) · Nature · doi:10.1038/350614a0 · Cited by 1,165
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Self-citationNeurotransmitter functions of mammalian tachykinins.
Otsuka, M., & Yoshioka, K. (1993) · Physiological Reviews · doi:10.1152/physrev.1993.73.2.229 · Cited by 1,080
Circuits and Circuit Disorders of the Basal Ganglia
DeLong, M. R., & Wichmann, T. (2007) · Archives of Neurology · doi:10.1001/archneur.64.1.20 · Cited by 1,074
Boolell, M., Mj, A., Sa, B., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Ih, O., & Gingell, C. (1996) · PubMed · Cited by 1,067
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition
Fitzgerald, P. B., Fountain, S., & Daskalakis, Z. J. (2006) · Clinical Neurophysiology · doi:10.1016/j.clinph.2006.06.712 · Cited by 1,024
Dopamine receptor pharmacology
Seeman, P., & Van Tol, H. H. M. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90323-9 · Cited by 956
Functional anatomy of the basal ganglia
Yelnik, J. (2002) · Movement Disorders · doi:10.1002/mds.10138 · Cited by 952
Translational control of long-lasting synaptic plasticity and memory
Costa-Mattioli, M., Sossin, W. S., Klann, E., & Sonenberg, N. (2009) · Neuron · doi:10.1016/j.neuron.2008.10.055 · Cited by 944
Molecular Structure and Physiological Functions of GABABReceptors
Bettler, B., Kaupmann, K., Mosbacher, J., & Gassmann, M. (2004) · Physiological Reviews · doi:10.1152/physrev.00036.2003 · Cited by 924
International Union of Pharmacology. XIII. Classification of Histamine Receptors
Hill, S. J., Ganellin, C. R., Timmerman, H., Schwartz, J. C., Shankley, N. P., Young, J. M., Schunack, W., Levi, R., & Haas, H. L. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01328-0 · Cited by 899
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895 · cited 2×
“Both serotonergic type 1A and type 1B (5-HT1A and 5-HT1B) receptors are coupled to a Gi/o protein (Nichols and Nichols, 2008).”
BackgroundNMDA receptor subunits: function and pharmacology
PAOLETTI, P., & NEYTON, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.011 · Cited by 887
The Neurobiology of Slow Synaptic Transmission
Greengard, P. (2001) · Science · doi:10.1126/science.294.5544.1024 · Cited by 867
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
The G protein-coupled receptor repertoires of human and mouse
Vassilatis, D. K., Hohmann, J. G., Zeng, H., Li, F., Ranchalis, J. E., Mortrud, M. T., Brown, A., Rodriguez, S. S., Weller, J. R., Wright, A. C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230374100 · Cited by 790
Graybiel, A. M., & Ragsdale, C. W. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.11.5723 · Cited by 784
Cannabinoid pharmacology: the first 66 years
Pertwee, R. G. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706406 · Cited by 782
Recent Advances in the Molecular Biology of Dopamine Receptors
Gingrich, J. A., & Caron, M. G. (1993) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.16.030193.001503 · Cited by 779
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons
Surmeier, D. J., Song, W.-J., & Yan, Z. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-20-06579.1996 · Cited by 747
DARPP-32: An Integrator of Neurotransmission
Svenningsson, P., Nishi, A., Fisone, G., Girault, J.-A., Nairn, A. C., & Greengard, P. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121415 · Cited by 720
Dopamine Receptor Binding Enhancement Accompanies Lesion-Induced Behavioral Supersensitivity
Creese, I., Burt, D. R., & Snyder, S. H. (1977) · Science · doi:10.1126/science.877576 · Cited by 712
γ-AMINOBUTYRIC ACID IN BRAIN: ITS FORMATION FROM GLUTAMIC ACID
Roberts, E., & Frankel, S. (1950) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50929-2 · Cited by 706
Jackson, I. M. D. (1982) · New England Journal of Medicine · doi:10.1056/nejm198201213060305 · Cited by 674
Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N., & Cenci, M. A. (2002) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01843.x · Cited by 664
Overton, H. A., Babbs, A. J., Doel, S. M., Fyfe, M. C. T., Gardner, L. S., Griffin, G., Jackson, H. C., Procter, M. J., Rasamison, C. M., Tang-Christensen, M., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.004 · Cited by 655
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
Cenci, M. A., Lee, C. S., & Björklund, A. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00285.x · Cited by 641
Histamine-immunoreactive nerve fibers in the rat brain
Panula, P., Pirvola, U., Auvinen, S., & Airaksinen, M. S. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90007-9 · Cited by 639
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Carta, M., Carlsson, T., Kirik, D., & Bjorklund, A. (2007) · Brain · doi:10.1093/brain/awm082 · Cited by 636
Extrinsic connections of the basal ganglia
Parent, A. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90105-j · Cited by 631
GABA and GABA Receptors in the Central Nervous System and Other Organs
Watanabe, M., Maemura, K., Kanbara, K., Tamayama, T., & Hayasaki, H. (2002) · International Review of Cytology · doi:10.1016/s0074-7696(02)13011-7 · Cited by 630
Mehta, A. K., & Ticku, M. K. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00052-6 · Cited by 625
Molecular Diversity of the Dopamine Receptors
Civelli, O., Bunzow, J. R., & Grandy, D. K. (1993) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.33.040193.001433 · Cited by 623
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
Anandamide and vanilloid TRPV1 receptors
Ross, R. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705467 · Cited by 604
International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List
Foord, S. M., Bonner, T. I., Neubig, R. R., Rosser, E. M., Pin, J.-P., Davenport, A. P., Spedding, M., & Harmar, A. J. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.5 · Cited by 592
Distribution, properties, and functional characteristics of three classes of histamine receptor.
Hill, S. J. (1990) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00039-0 · Cited by 591
Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum
Zhou, F.-M., Liang, Y., & Dani, J. A. (2001) · Nature Neuroscience · doi:10.1038/nn769 · Cited by 585
Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist
Pilla, M., Perachon, S., Sautel, F., Garrido, F., Mann, A., Wermuth, C. G., Schwartz, J.-C., Everitt, B. J., & Sokoloff, P. (1999) · Nature · doi:10.1038/22560 · Cited by 565
Maggio, J. E. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000305 · Cited by 547
Lukas, R. J., Changeux, J.-P., le Novère, N., Albuquerque, E. X., Balfour, D. J. K., Berg, D. K., Bertrand, D., Chiappinelli, V. A., Clarke, P. B. S., Collins, A. C., et al. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01406-6 · Cited by 537
Brahams, D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90821-x · Cited by 533
Molecular mechanisms of L-DOPA-induced dyskinesia
Jenner, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2471 · Cited by 523
Fox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
Self-citationMechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · cited 2×
“…that C. sativa comprises two active ingredients, D9-tetrahydrocannabinol, which acts as a CB1 agonist, and cannabidiol, which is a CB1 antagonist (Mechoulam et al., 2007); simultaneous stimulation and blockade of CB1 receptors with C. sativa might thus account for the lack of antidyskinetic…”
BackgroundAmantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Metman, L. V., Del Dotto, P., van den Munckhof, P., Fang, J., Mouradian, M. M., & Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5.1323 · Cited by 514
AGHAJANIAN, G. K., & MAREK, G. J. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00051-8 · Cited by 514
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511
Functional Selectivity and Biased Receptor Signaling
Kenakin, T. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173948 · Cited by 505
Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215250.82576.87 · Cited by 499
The mammalian tachykinin receptors
Maggi, C. A. (1995) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(94)00292-u · Cited by 486
Millan, M. J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.-A., & Newman-Tancredi, A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039867 · Cited by 484
Re-emergence of striatal cholinergic interneurons in movement disorders
Pisani, A., Bernardi, G., Ding, J., & Surmeier, D. J. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.07.008 · Cited by 466
Receptor basis for dopaminergic supersensitivity in Parkinson's disease
LEE, T., SEEMAN, P., RAJPUT, A., FARLEY, I. J., & HORNYKIEWICZ, O. (1978) · Nature · doi:10.1038/273059a0 · Cited by 446
Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J.-A., Herve, D., Greengard, P., & Fisone, G. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0852-07.2007 · Cited by 437
Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization
Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., de Benedetti, P., Goldberg, S. R., Neve, K., Fuxe, K., Agnati, L. F., Woods, A. S., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306451200 · Cited by 432
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 1×
“The synaptic vesicle glycoprotein 2A (SV2A), which is involved in exocytosis (Crowder et al., 1999), might play a role in the pathophysiology of dyskinesia, because it is currently the only known binding site of the anticonvulsant levetiracetam (Lynch et al.”
BackgroundAizman, O., Brismar, H., Uhlén, P., Zettergren, E., Levey, A. I., Forssberg, H., Greengard, P., & Aperia, A. (2000) · Nature Neuroscience · doi:10.1038/72929 · Cited by 415
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
Barbeau, A. (1969) · PubMed · Cited by 410
Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease
Halliday, G. M., Li, Y. W., Blumbergs, P. C., Joh, T. H., Cotton, R. G. H., Howe, P. R. C., Blessing, W. W., & Geffen, L. B. (1990) · Annals of Neurology · doi:10.1002/ana.410270405 · Cited by 408
Zoli, M., Moretti, M., Zanardi, A., McIntosh, J. M., Clementi, F., & Gotti, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08785.2002 · Cited by 407
mu opiate receptor: cDNA cloning and expression.
Wang, J. B., Imai, Y., Eppler, C. M., Gregor, P., Spivak, C. E., & Uhl, G. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10230 · Cited by 407
Glutamate: its role in learning, memory, and the aging brain
McEntee, W. J., & Crook, T. H. (1993) · Psychopharmacology · doi:10.1007/bf02253527 · Cited by 403
de la Fuente-Fernandez, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 402
Adenosine A2A receptors and basal ganglia physiology
Schiffmann, S. N., Fisone, G., Moresco, R., Cunha, R. A., & Ferré, S. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.05.001 · Cited by 397
Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia
Aubert, I., Guigoni, C., Håkansson, K., Li, Q., Dovero, S., Barthe, N., Bioulac, B. H., Gross, C. E., Fisone, G., Bloch, B., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20296 · Cited by 387
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
Bézard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., Gross, C., & Sokoloff, P. (2003) · Nature Medicine · doi:10.1038/nm875 · Cited by 383
Stocchi, F., Rascol, O., Kieburtz, K., Poewe, W., Jankovic, J., Tolosa, E., Barone, P., Lang, A. E., & Olanow, C. W. (2010) · Annals of Neurology · doi:10.1002/ana.22060 · Cited by 374
Dunah, A. W., & Standaert, D. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-15-05546.2001 · Cited by 373
RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING
Calne, R. Y., Lim, S., Samaan, A., Collier, D. S. J., Pollard, S. G., White, D. J. G., & Thiru, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90417-0 · Cited by 367
Ferré, S., Karcz-Kubicha, M., Hope, B. T., Popoli, P., Burgueño, J., Gutiérrez, M. A., Casadó, V., Fuxe, K., Goldberg, S. R., Lluis, C., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172393799 · Cited by 365
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors
Bateup, H. S., Santini, E., Shen, W., Birnbaum, S., Valjent, E., Surmeier, D. J., Fisone, G., Nestler, E. J., & Greengard, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009874107 · Cited by 360
75 years of opioid research: the exciting but vain quest for the Holy Grail
Corbett, A. D., Henderson, G., McKnight, A. T., & Paterson, S. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706435 · Cited by 358
Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease
Alonso-Frech, F. (2006) · Brain · doi:10.1093/brain/awl103 · Cited by 358
Levodopa‐induced dyskinesia: Review, observations, and speculations
Nutt, M. (1990) · Neurology · doi:10.1212/wnl.40.2.340 · Cited by 358
LeWitt, P. A., Guttman, M., Tetrud, J. W., Tuite, P. J., Mori, A., Chaikin, P., Sussman, N. M., & 6002‐US‐005 Study Group (2008) · Annals of Neurology · doi:10.1002/ana.21315 · Cited by 356
Isolation and structural organization of the human preproenkephalin B gene
Horikawa, S., Takai, T., Toyosato, M., Takahashi, H., Noda, M., Kakidani, H., Kubo, T., Hirose, T., Inayama, S., Hayashida, H., et al. (1983) · Nature · doi:10.1038/306611a0 · Cited by 352
Andersson, M., Hilbertson, A., & Cenci, M. A. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0259 · Cited by 350
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001) · Neurology · doi:10.1212/wnl.57.11.2108 · Cited by 349
Self-citationInduction of dopamine D 3 receptor expression as a mechanism of behavioral sensitization to levodopa
Bordet, R., Ridray, S., Carboni, S., Diaz, J., Sokoloff, P., & Schwartz, J.-C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3363 · Cited by 345
The Yin and Yang of dopamine release: a new perspective
GOTO, Y., OTANI, S., & GRACE, A. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.007 · Cited by 342
Pavón, N., Martín, A. B., Mendialdua, A., & Moratalla, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.044 · Cited by 341
The orphan opioid receptor and its endogenous ligand — nociceptin/orphanin FQ
Henderson, G., & McKnight, A. T. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)90645-3 · Cited by 331
Dysautonomia in Parkinson's disease: neurocardiological abnormalities
Goldstein, D. S. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00555-6 · Cited by 327
Adenosine A 2A receptor antagonist treatment of Parkinson’s disease
Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M. J., Mouradian, M. M., & Chase, T. N. (2003) · Neurology · doi:10.1212/01.wnl.0000073136.00548.d4 · Cited by 327
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias
Morgante, F., Espay, A. J., Gunraj, C., Lang, A. E., & Chen, R. (2006) · Brain · doi:10.1093/brain/awl031 · Cited by 327
McHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., & Bradshaw, H. B. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-44 · Cited by 323
Gubellini, P., Picconi, B., Bari, M., Battista, N., Calabresi, P., Centonze, D., Bernardi, G., Finazzi-Agrò, A., & Maccarrone, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-16-06900.2002 · Cited by 321
New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism
Kenakin, T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1875 · Cited by 317
Revisiting AMPA Receptors as an Antiepileptic Drug Target
Rogawski, M. A. (2011) · Epilepsy Currents · doi:10.5698/1535-7511-11.2.56 · Cited by 316
Organization of the basal ganglia: the importance of axonal collateralization
Parent, A., Sato, F., Wu, Y., Gauthier, J., Lévesque, M., & Parent, M. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00022-7 · Cited by 305
Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., & Matsunaga, M. (1999) · NeuroReport · doi:10.1097/00001756-199902250-00034 · Cited by 302
Rosenberg, G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7079-x · Cited by 300
Novel dopamine receptors half a decade later
Sokoloff, P., & Schwartz, J.-C. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)89044-6 · Cited by 295
Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys
Papa, S. M., & Chase, T. N. (1996) · Annals of Neurology · doi:10.1002/ana.410390505 · Cited by 292
Integration of biochemical signalling in spines
Kennedy, M. B., Beale, H. C., Carlisle, H. J., & Washburn, L. R. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1685 · Cited by 286
Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study
Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S. G., Fox, P., Wright, D., Hobart, J., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000140288.48796.8e · Cited by 286
Daugan, A., Grondin, P., Ruault, C., Le Monnier de Gouville, A.-C., Coste, H., Linget, J. M., Kirilovsky, J., Hyafil, F., & Labaudinière, R. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0300577 · Cited by 282
Westin, J. E., Vercammen, L., Strome, E. M., Konradi, C., & Cenci, M. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.032 · Cited by 277
Grace, A. A. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(94)01066-t · Cited by 274
A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia
Gardoni, F., Picconi, B., Ghiglieri, V., Polli, F., Bagetta, V., Bernardi, G., Cattabeni, F., Di Luca, M., & Calabresi, P. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5326-05.2006 · Cited by 269
Cenci, M. A., & Lundblad, M. (2007) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0925s41 · Cited by 266
Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene.
Mollereau, C., Simons, M. J., Soularue, P., Liners, F., Vassart, G., Meunier, J. C., & Parmentier, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8666 · Cited by 264
Dunah, A. W., Wang, Y., Yasuda, R. P., Kameyama, K., Huganir, R. L., Wolfe, B. B., & Standaert, D. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23206-5 · Cited by 263
Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., & Cenci, M. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06556.x · Cited by 263
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
Rylander, D., Parent, M., O'Sullivan, S. S., Dovero, S., Lees, A. J., Bezard, E., Descarries, L., & Cenci, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.22097 · Cited by 262
Goetz, C. G., Damier, P., Hicking, C., Laska, E., Müller, T., Olanow, C. W., Rascol, O., & Russ, H. (2007) · Movement Disorders · doi:10.1002/mds.21226 · Cited by 260
Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l -DOPA–Induced Dyskinesia
Santini, E., Heiman, M., Greengard, P., Valjent, E., & Fisone, G. (2009) · Science Signaling · doi:10.1126/scisignal.2000308 · Cited by 259
Hauser, R. A., Rascol, O., Korczyn, A. D., Jon Stoessl, A., Watts, R. L., Poewe, W., De Deyn, P. P., & Lang, A. E. (2007) · Movement Disorders · doi:10.1002/mds.21743 · Cited by 252
The Endomorphin System and Its Evolving Neurophysiological Role
Fichna, J., Janecka, A., Costentin, J., & Do Rego, J.-C. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.1.3 · Cited by 250
(2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<2::aid-ana2>3.0.co;2-b · Cited by 249
Muenter, M. D., & Tyce, G. M. (1971) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)07667-0 · Cited by 248
De La Fuente‐Fernández, R., Lu, J., Sossi, V., Jivan, S., Schulzer, M., Holden, J. E., Lee, C. S., Ruth, T. J., Calne, D. B., & Stoessl, A. J. (2001) · Annals of Neurology · doi:10.1002/ana.65 · Cited by 247
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
Thomas, A., Iacono, D., Luciano, A. L., Armellino, K., Iorio, A. D., & ONOFRJ, M. C. (2004) · PubMed Central · Cited by 246
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
Munoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., Kirik, D., Di Luca, M., Bjorklund, A., Bezard, E., et al. (2008) · Brain · doi:10.1093/brain/awn235 · Cited by 241
Lavoie, B., & Parent, A. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.902990102 · Cited by 239
Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study
Murata, M., Hasegawa, K., Kanazawa, I., & The Japan Zonisamide on PD Study Group (2007) · Neurology · doi:10.1212/01.wnl.0000250236.75053.16 · Cited by 238
Mouradian, M. M., Heuser, I. J. E., Baronti, F., & Chase, T. N. (1990) · Annals of Neurology · doi:10.1002/ana.410270105 · Cited by 236
Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification
Luquin, M. R., Scipioni, O., Vaamonde, J., Gershanik, O., & Obeso, J. A. (1992) · Movement Disorders · doi:10.1002/mds.870070204 · Cited by 235
Amantadine for Levodopa-Induced Dyskinesias: A 1-Year Follow-up Study
Metman, L. V., Del Dotto, P., LePoole, K., Konitsiotis, S., Fang, J., & Chase, T. N. (1999) · Archives of Neurology · doi:10.1001/archneur.56.11.1383 · Cited by 235
The natural history of treated Parkinson's disease in an incident, community based cohort
Evans, J. R., Mason, S. L., Williams-Gray, C. H., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240366 · Cited by 235
Metabotropic Glutamate Receptor-Mediated Long-Term Depression: Molecular Mechanisms
Gladding, C. M., Fitzjohn, S. M., & Molnár, E. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001735 · Cited by 233
REM Sleep Behavior Disorder in Parkinson’s Disease and Dementia with Lewy Bodies
Boeve, B. F., Silber, M. H., & Ferman, T. J. (2004) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704267465 · Cited by 233
A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression
Calabresi, P., Gubellini, P., Centonze, D., Sancesario, G., Morello, M., Giorgi, M., Pisani, A., & Bernardi, G. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02489.1999 · Cited by 232
Gαolf is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum
Corvol, J. C., Studler, J. M., Schonn, J. S., Girault, J. A., & Hervé, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00201.x · Cited by 229
Stocchi, F., Vacca, L., Ruggieri, S., & Olanow, C. W. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.905 · Cited by 229
The histamine H receptor as a new therapeutic target for inflammation
DEESCH, I., THURMOND, R., JONGEJAN, A., & LEURS, R. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.07.002 · Cited by 226
Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study
Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M., Thobois, S., Broussolle, E., & Rascol, O. (2004) · Neurology · doi:10.1212/01.wnl.0000110317.52453.6c · Cited by 224
Fahn, S., Libsch, L. R., & Cutler, R. W. (1971) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(71)90178-x · Cited by 224
Lévesque, M., & Parent, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502710102 · Cited by 222
Isolation and structural organization of the human preproenkephalin gene
Noda, M., Teranishi, Y., Takahashi, H., Toyosato, M., Notake, M., Nakanishi, S., & Numa, S. (1982) · Nature · doi:10.1038/297431a0 · Cited by 221
Calon, F., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Di Paolo, T. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.07.003 · Cited by 220
Dekundy, A., Lundblad, M., Danysz, W., & Cenci, M. A. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.01.013 · Cited by 219
Pearce, R. K. B., Jackson, M., Smith, L., Jenner, P., & Marsden, C. D. (1995) · Movement Disorders · doi:10.1002/mds.870100606 · Cited by 218
Sasaki, Y. F., Rothe, T., Premkumar, L. S., Das, S., Cui, J., Talantova, M. V., Wong, H.-K., Gong, X., Chan, S. F., Zhang, D., et al. (2002) · Journal of Neurophysiology · doi:10.1152/jn.00531.2001 · Cited by 212
Lee, C. S. (2000) · Brain · doi:10.1093/brain/123.7.1365 · Cited by 212
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
Calon, F. (2004) · Brain · doi:10.1093/brain/awh128 · Cited by 212
Synaptic vesicle protein 2 enhances release probability at quiescent synapses
Custer, K. L., Austin, N. S., Sullivan, J. M., & Bajjalieh, S. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2699-05.2006 · Cited by 211
Continuous dopamine-receptor stimulation in early Parkinson's disease
Olanow, C. W., Schapira, A. H. V., & Rascol, O. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00030-6 · Cited by 208
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
Hauser, R. A., Shulman, L. M., Trugman, J. M., Roberts, J. W., Mori, A., Ballerini, R., & Sussman, N. M. (2008) · Movement Disorders · doi:10.1002/mds.22095 · Cited by 207
Histamine receptors in the CNS as targets for therapeutic intervention
Passani, M. B., & Blandina, P. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.01.003 · Cited by 206
Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M., & Cenci, M. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04456.x · Cited by 205
Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Parkinson Study Group CALM Cohort Investigators (2009) · Archives of Neurology · doi:10.1001/archneur.66.1.nct90001 · Cited by 205
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures
Porter, R. J., Partiot, A., Sachdeo, R., Nohria, V., & Alves, W. M. (2007) · Neurology · doi:10.1212/01.wnl.0000259034.45049.00 · Cited by 204
Olanow, C. W., Fahn, S., Muenter, M., Klawans, H., Hurtig, H., Stern, M., Shoulson, I., Kurlan, R., Grimes, J. D., Jankovic, J., et al. (1994) · Movement Disorders · doi:10.1002/mds.870090107 · Cited by 204
Bibbiani, F., Oh, J. D., Petzer, J. P., Castagnoli, N., Chen, J.-F., Schwarzschild, M. A., & Chase, T. N. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00250-4 · Cited by 204
Beneficial effects of amantadine onL-dopa-induced dyskinesias in Parkinson's disease
Luginger, E., Wenning, G. K., B�sch, S., & Poewe, W. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5<873::aid-mds1017>3.0.co;2-i · Cited by 203
Regional Differences in Cannabinoid Receptor/G-protein Coupling in Rat Brain
Breivogel, C. S., Sim, L. J., & Childers, S. R. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36967-8 · Cited by 202
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia
Lundblad, M., Usiello, A., Carta, M., Håkansson, K., Fisone, G., & Cenci, M. A. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.02.002 · Cited by 202
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E., & Chase, T. N. (2000) · Neurology · doi:10.1212/wnl.54.8.1589 · Cited by 201
Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems
Alagarsamy, S., Marino, M. J., Rouse, S. T., Gereau, R. W., Heinemann, S. F., & Conn, P. J. (1999) · Nature Neuroscience · doi:10.1038/6338 · Cited by 199
van der Stelt, M., Fox, S. H., Hill, M., Crossman, A. R., Petrosino, S., Di Marzo, V., & Brotchie, J. M. (2005) · The FASEB Journal · doi:10.1096/fj.04-3010fje · Cited by 199
Self-citationMontastruc, J. L., Rascol, O., Senard, J. M., & Rascol, A. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.9.1034 · Cited by 198
Burnashev, N., Villarroel, A., & Sakmann, B. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021674 · Cited by 197
Morgese, M. G., Cassano, T., Cuomo, V., & Giuffrida, A. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.021 · Cited by 196
Péchevis, M., Clarke, C. E., Vieregge, P., Khoshnood, B., Deschaseaux‐Voinet, C., Berdeaux, G., Ziegler, M., & on behalf of the Trial Study Group (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01096.x · Cited by 196
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Self-citationDaugan, A., Grondin, P., Ruault, C., Le Monnier de Gouville, A.-C., Coste, H., Kirilovsky, J., Hyafil, F., & Labaudinière, R. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030056e · Cited by 195
Molecular determinants of AMPA receptor subunit assembly
Greger, I. H., Ziff, E. B., & Penn, A. C. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.005 · Cited by 194
Cicchetti, F., Prensa, L., Wu, Y., & Parent, A. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00039-4 · Cited by 193
Boraud, T., Bezard, E., Bioulac, B., & Gross, C. E. (2001) · Brain · doi:10.1093/brain/124.3.546 · Cited by 193
Effects of apomorphine on globus pallidus neurons in parkinsonian patients
Hutchison, W. D., Levy, R., Dostrovsky, J. O., Lozano, A. M., & Lang, A. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420513 · Cited by 192
Cited by
Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease
Qu, M., Lin, Q., Huang, L., Fu, Y., Wang, L., He, S., Fu, Y., Yang, S., Zhang, Z., Zhang, L., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.035 · Cited by 543
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., & Lang, A. E. (2018) · Annals of Neurology · doi:10.1002/ana.25364 · Cited by 340
Self-citationCilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
Zhu, Z., Yang, C., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S. G., Liu, J., Wang, Z., Tong, B. C.-K., Song, J., Lu, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030728 · Cited by 263
Bortolanza, M., do Nascimento, G. C., Raisman‐Vozari, R., & Del‐Bel, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15439 · Cited by 33
Metadata
- Authors
- Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 65
- Issue
- 1
- Pages
- 171-222
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2107758668
- Cited by
- 324
- References
- 558
- FWCI
- 21.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.